Enables several functions, including ATPase binding activity; PDZ domain binding activity; and aspartic endopeptidase activity, intramembrane cleaving. Involved in several processes, including amyloid-beta formation; regulation of gene expression; and regulation of phosphate metabolic process. Acts upstream of or within cell-cell adhesion and endoplasmic reticulum calcium ion homeostasis. Located in several cellular components, including aggresome; endoplasmic reticulum; and nucleus. Part of gamma-secretase complex. Is active in dendrite. Implicated in Alzheimer's disease (multiple); dilated cardiomyopathy 1U; frontotemporal dementia (multiple); and hidradenitis suppurativa.
Trenbolone Acetate analog inhibits the reaction [Dihydrotestosterone results in increased expression of PSEN1 protein] and trilostane inhibits the reaction [Trenbolone Acetate analog inhibits the reaction [Dihydrotestosterone results in increased expression of PSEN1 protein]]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of galactosylhydroxylysine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of galactosylhydroxylysine]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Uric Acid and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Uric Acid]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Aconitic Acid and IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Aconitic Acid]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate]
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GABRA1 protein] more ...
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Choline and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Choline]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Citric Acid and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Citric Acid]
[PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] more ...
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of gluconic acid and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of gluconic acid]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fumaric acid and IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fumaric acid]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glyceraldehyde 3-Phosphate and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glyceraldehyde 3-Phosphate]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glycine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glycine]
Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter] and Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter]
MIR141 mRNA promotes the reaction [Palmitic Acid results in decreased expression of PSEN1 mRNA] and MIR141 mRNA promotes the reaction [Palmitic Acid results in decreased expression of PSEN1 protein]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Kynurenine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Kynurenine]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Arginine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Arginine]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Cysteine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Cysteine]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glutamic Acid and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glutamic Acid]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Histidine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Histidine]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Methionine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Methionine]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid]
[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA and Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA]
methysticin inhibits the reaction [[PSEN1 protein co-treated with APP protein] results in increased secretion of IL17A protein] and methysticin inhibits the reaction [[PSEN1 protein co-treated with APP protein] results in increased secretion of TNF protein]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Acetylglucosamine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Acetylglucosamine]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Acetylglucosamine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Acetylglucosamine]
[PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Oleic Acid and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Oleic Acid]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Ornithine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Ornithine]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of palmitoleic acid and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of palmitoleic acid]
[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA and Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Pregabalin and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Pregabalin]
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Succinic Acid] and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Succinic Acid]
ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of BCL2 protein] more ...
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of tetracosapentaenoic acid and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of tetracosapentaenoic acid]
trilostane inhibits the reaction [Trenbolone Acetate analog inhibits the reaction [Dihydrotestosterone results in increased expression of PSEN1 protein]]
[Tunicamycin co-treated with APP protein modified form] results in increased expression of PSEN1 mRNA and ATF4 protein affects the reaction [[Tunicamycin co-treated with APP protein modified form] results in increased expression of PSEN1 mRNA]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Valine and PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Valine]